Skip to main content
$0.57 $0.02 (3.8%)

04:00 PM EDT on 10/15/21

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

CAPS Rating: 1 out of 5

Current Price $0.57 Mkt Cap $203.8M
Open $0.56 P/E Ratio 0.00
Prev. Close $0.57 Div. (Yield) $0.00 (0.0%)
Daily Range $0.55 - $0.57 Volume 14,832,731
52-Wk Range $0.51 - $2.12 Avg. Daily Vol. 13,182,764


How do you think NASDAQ:TNXP will perform against the market?

Add Stock to CAPS Watchlist

All Players

26 Outperform
8 Underperform

All-Star Players

2 Outperform
6 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:TNXP Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

TerryHogan (99.11)
Submitted December 14, 2018

[Sung to the tune of 'Supercalifragilisticexpialidocious']The MD&A from Tonix corp is braggadocious.4 years of cash flows makes for reading that is quite atrocious.If you put your money here returns will be ferocious!You'll end up taxonified as… More



Fools bullish on NASDAQ:TNXP are also bullish on:

Fools bearish on NASDAQ:TNXP are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about TNXP.


Member Avatar mdriver78 (75.36) Submitted: 9/24/2020 10:00:04 AM : Outperform Start Price: $1.66 NASDAQ:TNXP Score: -80.01

Tonix is developing a drug called cyclobenzaprine for treating fibromyalgia. This drug has been used orally for more than 40 years, so its effects are well known and characterized. Tonix, however, has re-formulated the drug using its delivery technology so that it can be absorbed sublingually, bypassing the digestive tract. This avoids first pass metabolism, reducing creation of active metabolites and off target effects and helps promote rapid absorption of the drug.

Tonix has had a rocky road in developing this drug, which it calls TNX-102. Past trials have failed to show statistical improvement in pain relief when compared to placebo, but the experience has helped the company fine tune its dosing and trial protocols, along with interaction with the FDA.

Right now, the company is running a Phase 3 for TNX-102 in fibromyalgia, and very soon the company expects the trial will produce data. Interim data are expected by the end of September, and topline data by December.

If data are good, showing that TNX-102 works to help treat fibromyalgia, it could be a big boon for TNXP shares, boosting them to a multiple of where they are today. Strong trial results will enable the Tonix to submit a new drug application with the FDA and, if approved, begin marketing the drug.

But there’s a great deal more going on at Tonix. TNX-102 is is in Phase 3 trials for post-traumatic stress disorder (PTSD) and ready to enter Phase 2 trials for Alzheimer’s agitation and alcohol use disorder. The company has a different drug, TNX-1300 in Phase 2 for cocaine intoxication, and TNX-601 in Phase 1 for depression, PTSD, and neurocognitive dysfunction from corticosteroids.

On top the the company’s central nervous system portfolio, there is a robust immunological pipeline including three different COVID-19 vaccines, two smallpox preventing vaccines, an organ transplant rejection and autoimmune condition vaccine, a gastric and pancreatic cancer vaccine, and a vaccine designed to protect against radiation damage. The company expects animal data from its COVID-19 programs to read out at the end of this year.

Success in any of these other programs could boost TNXP’s price well beyond where it is today, but the main event right now is the imminent Phase 3 readout from the company’s lead drug in fibromyalgia. Tonix reports $55 million as of its last quarterly filing, exclusive of a $9.6 million capital raise in July. That’s plenty of cash to get to an interim analysis later this month, as well as a final readout by the end of the year.

As noted, the market for fibromyalgia is potentially in the multibillion dollar range. Accessing that market successfully starts with a positive Phase 3 readout. Hitting that goal means Tonix would potentially be worth hundreds of percentage points higher than it is today.


Member Avatar PestAssassin0065 (83.37) Submitted: 12/27/2018 3:28:02 PM : Underperform Start Price: $7.00 NASDAQ:TNXP Score: +153.97

A holding company that holds nothing but heartache...


Member Avatar oscillation (75.19) Submitted: 9/21/2016 5:33:38 PM : Outperform Start Price: $73.00 NASDAQ:TNXP Score: -204.59



Find the members with the highest scoring picks in TNXP.

Score Leader


whatsthepoint (99.59) Score: +588.86

The Score Leader is the player with the highest score across all their picks in TNXP.

Member Name Member
Call Time
Score Commentary
NHWeston102 78.08 5/19/2016 2/4/2021 Underperform 1Y $262.00 -99.78% +118.77% +218.55 1 Comment
Slickrick9565 46.01 10/4/2016 Underperform 5Y $74.10 -99.23% +107.63% +206.86 0 Comment
ksrinivasan2 95.56 1/25/2018 Underperform 5Y $39.90 -98.57% +56.83% +155.40 0 Comment
PestAssassin0065 83.37 11/29/2018 Underperform 5Y $7.00 -91.83% +62.14% +153.97 1 Comment
OttoBismarck 98.93 12/11/2018 Underperform 5Y $2.76 -79.28% +67.86% +147.14 0 Comment
TSIF 99.99 3/8/2019 Underperform 1Y $3.16 -81.92% +62.98% +144.90 0 Comment
zzlangerhans 99.00 3/8/2019 Underperform 1Y $2.72 -78.99% +62.98% +141.97 0 Comment
whatsthepoint 99.59 2/8/2021 Underperform 5Y $1.66 -65.53% +14.49% +80.01 0 Comment
birdup 26.21 2/8/2021 Outperform 5Y $1.66 -65.53% +14.49% -80.01 0 Comment
drugtrader 85.91 2/8/2021 Outperform 5Y $1.66 -65.53% +14.49% -80.01 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for TNXP.